Integrated Search Menu

Stephen Munk

Profile photo
Professor of Practice, Deputy Director, Biodesign Institute
Faculty, TEMPE Campus, Mailcode 5001
Deputy Director
University Staff, TEMPE Campus, Mailcode 5001
Biography

Stephen Munk, Ph.D. joined the Biodesign Institute at ASU as its Deputy Director in October of 2017.  He received his B.S. degree in chemistry at ASU, and then earned his Ph.D. in organic synthesis at The University of California at Berkeley under the supervision of Henry Rapoport and subsequently completed an American Cancer Society Postdoctoral Fellowship with Dale Boger at Purdue conducting studies involved in the sequence selective interaction of small molecules with DNA using the tools of molecular biology.  He is experienced in drug discovery, development, and manufacturing both as a scientist and as a manager. Dr. Munk was the CEO and President of Ash Stevens Inc., a full service Active Pharmaceutical Ingredient (API) development and manufacturing organization, from 1997-2017.  Under his leadership, Ash Stevens received twelve FDA approvals to manufacture innovator drug substances.  These approvals include the oncology drugs bortezomib (Velcade), busulfan (Busulfex), clofarabine (Clolar), and 5-azacitidine (Vidaza), ponatinib (Iclusig) and ixazomib (Ninlaro).  Ash Stevens received six NIH research contacts under his leadership including four competing contract renewals.  Prior to joining Ash Stevens in 1997, he worked at Allergan, Inc. initially as a medicinal chemist and subsequently, the co-team leader of the adrenergic drug discovery team. 

His work has been summarized in a number of publications and patents.  He is a co-author of the 2016 book - Managing the Drug Discovery Process: How to Make It More Efficient and Cost-Effective.  Dr. Munk served as an Adjunct Professor of Chemistry at Wayne State University and on the Henry Ford Community College Biotechnology Advisory Board.  He served on the Steering Committee of the Chemistry in Cancer Research Working Group of the American Association for Cancer Research (CICR-AACR; 2008-2010; 2011-2013; Chairman, 2014), the Board of Directors of MichBio (2008 – 2014; Chairman 2010 - 2014), the Michigan Biotechnology Innovation Organization (BIO) affiliate.

Education

04/88 to 04/91 American Cancer Society Postdoctoral Fellow (D. Boger)     Purdue University, West Lafayette, IN 
 
08/79 to 07/85 Ph.D., Organic Chemistry (H. Rapoport)  Thesis Title: Tetrahydropurines  University of California at Berkeley, Berkeley, CA 
 
01/76 to 05/79 B.S., Chemistry, cum laude  Undergraduate Research Participant (G. Yuen)  Arizona State University, Tempe, AZ 

Board

2010 to 2013             SOCMA Board of Governors

2009 to 2016            Henry Ford Community College Biotechnology Advisory Board

2011 to 2015             American Association for Cancer Research /

                                 Chemistry in Cancer Research (AACR-CICR); Chairman (2014)

2008 to 2010             American Association for Cancer Research /

                                  Chemistry in Cancer Research (AACR-CICR) Steering Committee

2008 to 2014             MichBio Board of Directors; Chairman, 2009-2014

2007 to 2010             SciTech Development Scientific Advisory Board

2000 to 2006             Advisory Board Member, The Center for Biomedical Research (CBR)

                                  Oakland University’s College of Arts & Sciences

Industry Positions

01/97 to 04/17              Ash Stevens Inc., Riverview MI; Part of Piramal since 2016

                                     CEO & President; Member, Board of Directors

 

05/91 to 12/96              Drug Discovery, Allergan, Inc., Irvine, CA

                                     Co-Team Leader, a2-Adrenergic Discovery Team

                                      Principal Scientist, Medicinal Chemistry

                                      Senior Scientist, Medicinal Chemistry

                                      Scientist, Medicinal Chemistry